Literature DB >> 1196552

Prognostic significance of cervical lesion size and pelvic node metastases in cervical carcinoma.

M S Piver, W S Chung.   

Abstract

There were 289 radical hysterectomies performed at Roswell Park Memorial Institute for Stage IB, IIA, and recurrent cervical cancer from 1957 to 1967. The prognostic significance of cervical lesion size, pelvic node metastases, and type of radical hysterectomy have been evaluated. Excellent 5-year survival rates for women with Stage IB cervical carcinoma were associated with cervical lesions measuring less than 3 cm and resected pelvic lymph nodes which did not contain metastatic cancer. In addition, 31% of women with recurrent cervical cancer treated by radical hysterectomy survived 5 years without recurrence.

Entities:  

Mesh:

Year:  1975        PMID: 1196552

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  30 in total

1.  Staging of uterine cervical cancer with MRI: guidelines of the European Society of Urogenital Radiology.

Authors:  Corinne Balleyguier; E Sala; T Da Cunha; A Bergman; B Brkljacic; F Danza; R Forstner; B Hamm; R Kubik-Huch; C Lopez; R Manfredi; J McHugo; L Oleaga; K Togashi; K Kinkel
Journal:  Eur Radiol       Date:  2010-11-10       Impact factor: 5.315

2.  The twenty-first century role of Piver-Rutledge type III radical hysterectomy and FIGO stage IA, IB1, and IB2 cervical cancer in the era of robotic surgery: a personal perspective.

Authors:  M Steven Piver; Ali Ghomi
Journal:  J Gynecol Oncol       Date:  2010-12-31       Impact factor: 4.401

3.  In reply.

Authors:  Woo-Young Kim; Suk-Joon Chang; Hee-Sug Ryu
Journal:  J Gynecol Oncol       Date:  2009-06-29       Impact factor: 4.401

4.  Prognostic significance of positive lymph node number in early cervical cancer.

Authors:  Jung-Woo Park; Jong Woon Bae
Journal:  Mol Clin Oncol       Date:  2016-03-30

5.  Changes in prevalence and clinical characteristics of cervical cancer in the People's Republic of China: a study of 10,012 cases from a nationwide working group.

Authors:  Shuang Li; Ting Hu; Weiguo Lv; Hang Zhou; Xiong Li; Ru Yang; Yao Jia; Kecheng Huang; Zhilan Chen; Shaoshuai Wang; Fangxu Tang; Qinghua Zhang; Jian Shen; Jin Zhou; Ling Xi; Dongrui Deng; Hui Wang; Shixuan Wang; Xing Xie; Ding Ma
Journal:  Oncologist       Date:  2013-09-16

6.  Patients treated with neoadjuvant chemotherapy + radical surgery + adjuvant chemotherapy in locally advanced cervical cancer: long-term outcomes, survival and prognostic factors in a single-center 10-year follow-up.

Authors:  Daniela Luvero; Francesco Plotti; Alessia Aloisi; Stella Capriglione; Roberto Ricciardi; Andrea Miranda; Salvatore Lopez; Giuseppe Scaletta; Giovanna De Luca; Pierluigi Benedetti-Panici; Roberto Angioli
Journal:  Med Oncol       Date:  2016-08-30       Impact factor: 3.064

7.  Human papillomavirus DNA and p53 status in stage IB bulky cervical cancer.

Authors:  C A Chen; T M Chen; C C Wu; C F Chang; C Y Hsieh
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

Review 8.  [Current TNM/FIGO classification for cervical and endometrial cancer as well as malignant mixed müllerian tumors. Facts and background].

Authors:  L-C Horn; K Schierle; D Schmidt; U Ulrich; A Liebmann; C Wittekind
Journal:  Pathologe       Date:  2011-05       Impact factor: 1.011

9.  Survival benefits of neoadjuvant chemotherapy followed by radical surgery versus radiotherapy in locally advanced chemoresistant cervical cancer.

Authors:  Youn Seok Choi; Jeong-Im Sin; Ju Hyun Kim; Gi Won Ye; Im Hee Shin; Tae Sung Lee
Journal:  J Korean Med Sci       Date:  2006-08       Impact factor: 2.153

10.  Feasibility and safety of carboplatin plus paclitaxel as neoadjuvant chemotherapy for locally advanced cervical cancer: a pilot study.

Authors:  Roberto Angioli; Francesco Plotti; Daniela Luvero; Alessia Aloisi; Federica Guzzo; Stella Capriglione; Corrado Terranova; Carlo De Cicco Nardone; Pierluigi Benedetti-Panici
Journal:  Tumour Biol       Date:  2014-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.